Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 0.65 |
| ▸ | CDK2 | P24941 | 20/20 | 0.65 |
| ▸ | CCNA1 | P78396 | 20/20 | 0.65 |
| ▸ | CDK4 | P11802 | 2/20 | 0.65 |
| ▸ | CCND3 | P30281 | 1/20 | 0.65 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 6/20 | 0.59 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150882 | 0.84 | CCNA2 (0.78) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4157099 | 0.83 | CCNA2 (0.76) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4154986 | 0.83 | CCNA2 (0.74) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL1558494 | 0.81 | TTK (0.69) | CCNA2CDK2CCNA1CDK4AURKA | |
| SCHEMBL4150670 | 0.81 | CCNA2 (0.64) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4154687 | 0.80 | CDK2 (1.00) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4214742 | 0.79 | CCNA2 (0.63) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4160850 | 0.78 | CCNA2 (0.79) | CCNA2CDK2CCNA1CDK4AURKA | |
| SCHEMBL4150917 | 0.78 | CDK2 (0.73) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4163983 | 0.78 | CDK2 (0.70) | CCNA2CDK2CCNA1CDK4CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
| US-9637497-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences, S.R.L. (IT) | 2017-05-02 | — | — | US | disclosed |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-02-23 | — | — | US | disclosed |
| US-9464090-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-11 | — | — | US | disclosed |
| US-20150158876-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-8981089-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-20130338148-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-19 | — | — | US | disclosed |
| EP-1636236-B1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-09 | — | — | EP | disclosed |
| US-8541429-B2 | Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1207/4885CDK2 49/4885CCNA1 933/4885 |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20150158876-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1207/4885CDK2 49/4885CCNA1 933/4885 |
| US-20130338148-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP3K19 | CCNA2 1362/4885CDK2 52/4885CCNA1 1080/4885 |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.